Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.

Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer.

Br J Cancer. 2018 Apr;118(8):1084-1088. doi: 10.1038/s41416-018-0005-1. Epub 2018 Mar 9.

PMID:
29523831
2.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.

Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer.

Br J Cancer. 2018 Apr;118(7):947-954. doi: 10.1038/s41416-018-0004-2. Epub 2018 Mar 8.

PMID:
29515256
3.

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.

Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer.

Ann Surg. 2017 Oct 24. doi: 10.1097/SLA.0000000000002557. [Epub ahead of print]

PMID:
29068800
4.

RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.

Anderson G, Mackay N, Gilroy K, Hay J, Borland G, McDonald A, Bell M, Hassanudin SA, Cameron E, Neil JC, Kilbey A.

J Cell Biochem. 2018 Mar;119(3):2750-2762. doi: 10.1002/jcb.26443. Epub 2017 Nov 20.

5.

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.

Hurt CN, Falk S, Crosby T, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T, Mukherjee S.

Br J Cancer. 2017 May 9;116(10):1264-1270. doi: 10.1038/bjc.2017.95. Epub 2017 Apr 4.

6.

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.

Lote H, Spiteri I, Ermini L, Vatsiou A, Roy A, McDonald A, Maka N, Balsitis M, Bose N, Simbolo M, Mafficini A, Lampis A, Hahne JC, Trevisani F, Eltahir Z, Mentrasti G, Findlay C, Kalkman EAJ, Punta M, Werner B, Lise S, Aktipis A, Maley C, Greaves M, Braconi C, White J, Fassan M, Scarpa A, Sottoriva A, Valeri N.

Ann Oncol. 2017 Jun 1;28(6):1243-1249. doi: 10.1093/annonc/mdx074.

7.

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer.

Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.

8.

Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.

Kilbey A, Terry A, Wotton S, Borland G, Zhang Q, Mackay N, McDonald A, Bell M, Wakelam MJ, Cameron ER, Neil JC.

J Cell Biochem. 2017 Jun;118(6):1432-1441. doi: 10.1002/jcb.25802. Epub 2017 Jan 10.

9.

Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.

Borland G, Kilbey A, Hay J, Gilroy K, Terry A, Mackay N, Bell M, McDonald A, Mills K, Cameron E, Neil JC.

Oncotarget. 2016 Apr 26;7(17):22973-87. doi: 10.18632/oncotarget.8554.

10.

Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer.

Fulton BA, Gray J, McDonald A, McIntosh D, MacLaren V, Hennessy A, Grose D.

J Gastrointest Oncol. 2016 Apr;7(2):166-72. doi: 10.3978/j.issn.2078-6891.2015.068.

11.

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.

Hurt CN, Mukherjee S, Bridgewater J, Falk S, Crosby T, McDonald A, Joseph G, Staffurth J, Abrams RA, Blazeby JM, Bridges S, Dutton P, Griffiths G, Maughan T, Johnson C.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):810-8. doi: 10.1016/j.ijrobp.2015.08.026. Epub 2015 Aug 24.

12.

A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.

Roxburgh P, Lumsden GR, Paul J, Harden S, Sweeting L, James A, Crellin A, Morrison R, Evans TR, McDonald AC.

Cancer Chemother Pharmacol. 2014 Jul;74(1):131-9. doi: 10.1007/s00280-014-2470-4. Epub 2014 May 13.

PMID:
24819683
13.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW; European Study Group for Pancreatic Cancer.

J Natl Cancer Inst. 2014 Jan;106(1):djt347. doi: 10.1093/jnci/djt347. Epub 2013 Dec 3.

PMID:
24301456
14.

Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer.

Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC.

Colorectal Dis. 2012 Oct;14(10):e701-7. doi: 10.1111/j.1463-1318.2012.03147.x.

PMID:
22731833
15.

Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors.

Roxburgh C, McDonald A, Salmond J, Oien K, Anderson J, McKee R, Horgan P, McMillan D.

Int J Colorectal Dis. 2011 Apr;26(4):483-92. doi: 10.1007/s00384-010-1120-5. Epub 2011 Jan 7.

PMID:
21212966
16.

A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.

Obi EE, McDonald A, Kemp E.

Cutan Ocul Toxicol. 2011 Jun;30(2):157-9. doi: 10.3109/15569527.2010.532846. Epub 2010 Nov 16.

PMID:
21077799
17.

The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer.

Low G, Tho LM, Leen E, Wiebe E, Kakumanu S, McDonald AC, Poon FW.

Surgeon. 2008 Aug;6(4):222-31. Review.

PMID:
18697365
18.

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.

Crumley AB, Stuart RC, McKernan M, McDonald AC, McMillan DC.

J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e325-9. Epub 2007 Jul 20.

PMID:
17645468
19.

A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.

MacLeod A, Branch A, Cassidy J, McDonald A, Mohammed N, MacDonald L.

Eur J Oncol Nurs. 2007 Jul;11(3):247-54. Epub 2006 Dec 26.

PMID:
17188937
20.

Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning.

Tho LM, Glegg M, Paterson J, Yap C, MacLeod A, McCabe M, McDonald AC.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):505-13. Epub 2006 Jul 31.

PMID:
16879928

Supplemental Content

Loading ...
Support Center